We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,481 hedge funds and large institutions have $102B invested in Bristol-Myers Squibb in 2023 Q2 according to their latest regulatory filings, with 126 funds opening new positions, 947 increasing their positions, 1,065 reducing their positions, and 163 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more call options, than puts

Call options by funds: $1.43B | Put options by funds: $995M

0.44% less ownership

Funds ownership: 76.44%76% (-0.44%)

2% less funds holding

Funds holding: 2,5412,481 (-60)

8% less capital invested

Capital invested by funds: $111B → $102B (-$8.64B)

11% less repeat investments, than reductions

Existing positions increased: 947 | Existing positions reduced: 1,065

23% less first-time investments, than exits

New positions opened: 126 | Existing positions closed: 163

35% less funds holding in top 10

Funds holding in top 10: 6844 (-24)

Holders
2,481
Holders Change
-60
Holders Change %
-2.36%
% of All Funds
38.95%
Holding in Top 10
44
Holding in Top 10 Change
-24
Holding in Top 10 Change %
-35.29%
% of All Funds
0.69%
New
126
Increased
947
Reduced
1,065
Closed
163
Calls
$1.43B
Puts
$995M
Net Calls
+$431M
Net Calls Change
-$137M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1176
Ategra Capital Management
Virginia
$1.35M +$119K +1,780 +9%
HIA
1177
Harvest Investment Advisors
Florida
$1.35M -$2.01K -30 -0.1%
QPWM
1178
Quadrant Private Wealth Management
Pennsylvania
$1.35M +$1.21K +18 +0.1%
RWM
1179
Ritholtz Wealth Management
New York
$1.35M -$207K -3,083 -13%
MSR
1180
Main Street Research
Connecticut
$1.34M
AIA
1181
Affinity Investment Advisors
California
$1.34M -$331K -4,934 -19%
LAM
1182
L2 Asset Management
Massachusetts
$1.34M -$2.6M -38,838 -64%
BLC
1183
Brown, Lisle/Cummings
Rhode Island
$1.34M -$256K -3,823 -15%
BC
1184
Bridgefront Capital
Texas
$1.34M +$1.4M +20,934 New
PAM
1185
Palisade Asset Management
Minnesota
$1.34M +$9.72K +145 +0.7%
CNC
1186
Citizens & Northern Corp
Pennsylvania
$1.34M -$6.37K -95 -0.5%
FRM
1187
Fox Run Management
Connecticut
$1.33M +$1.4M +20,816 New
WWM
1188
Western Wealth Management
Colorado
$1.33M -$75.3K -1,123 -5%
HCM
1189
Highlander Capital Management
New Jersey
$1.33M +$16.8K +250 +1%
GRP
1190
Global Retirement Partners
California
$1.33M +$105K +1,573 +8%
OIA
1191
Optimum Investment Advisors
Illinois
$1.32M +$87.3K +1,302 +7%
ZIC
1192
ZWJ Investment Counsel
Georgia
$1.32M -$36.9K -550 -3%
OWM
1193
Opes Wealth Management
California
$1.32M +$2.01K +30 +0.1%
NPT
1194
Nixon Peabody Trust
Massachusetts
$1.31M -$697K -10,392 -34%
CFA
1195
Camarda Financial Advisors
Florida
$1.31M +$53.8K +803 +4%
BL
1196
Balentine LLC
Georgia
$1.31M -$85.4K -1,273 -6%
CCP
1197
Carmel Capital Partners
California
$1.31M +$1.41K +21 +0.1%
CCG
1198
Coastwise Capital Group
California
$1.31M +$127K +1,895 +10%
AB
1199
Atlas Brown
Kentucky
$1.3M +$5.03K +75 +0.4%
JIP
1200
Jaffetilchin Investment Partners
Florida
$1.3M +$25.8K +384 +2%

BMY Hedge Fund Activity: Q2 2023 in Review

2,481 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2023, worth a combined $102B — down 7.8% from $111B a quarter earlier.

Sellers outnumbered buyers: 163 funds closed out of BMY and 126 opened new positions — a net loss of 37 holders — while 1,065 trimmed existing stakes and 947 added.

The largest buyer was Capital International Investors, adding an estimated $528M. The largest seller was Bank of America, cutting an estimated $634M.

  • 2,481 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2023, down from 2,541 in Q1 2023.
  • Funds reported $102B of Bristol-Myers Squibb stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 126 funds opened new Bristol-Myers Squibb positions in Q2 2023 and 163 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2023 was Capital International Investors, an estimated $528M added.
  • The largest Bristol-Myers Squibb seller in Q2 2023 was Bank of America, an estimated $634M sold.

Based on aggregated 13F filings for Q2 2023.